Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: T cell receptor-based cancer therapeutics - Bellicum Pharmaceuticals/Leiden University Medical Center

Next Previous
Drug Profile

Research programme: T cell receptor-based cancer therapeutics - Bellicum Pharmaceuticals/Leiden University Medical Center

Alternative Names: High-affinity T cell receptor product candidates - Bellicum Pharmaceuticals/LUMC; TCR cell therapies - Bellicum Pharmaceuticals/LUMC; TCRs - Bellicum Pharmaceuticals/Leiden University Medical Center

Latest Information Update: 05 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bellicum Pharmaceuticals; Leiden University Medical Center
  • Developer Leiden University Medical Center
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 23 Feb 2024 Discontinued for Cancer in Netherlands (Parenteral) before February 2024 as Bellicum Pharmaceuticals has winded down its business and no longer active
  • 28 Jul 2020 No recent reports of development identified for research development in Cancer in Netherlands (Parenteral)
  • 02 Jun 2016 Bellicum Pharmaceuticals and Leiden University Medical Center agree to co-develop T cell receptor-based therapeutics in Netherlands for Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top